Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Jul;43(7):4095-4097.
doi: 10.1007/s10072-022-05961-9. Epub 2022 Mar 23.

Anti-SARS-Cov2 vaccination at the time of the COVID-19 pandemic: suspected adverse events reporting is the milestone of post-marketing surveillance

Alice Mariottini  1   2 , Anna Maria Repice  2 , Alessandro Barilaro  2 , Luca Massacesi  3   4
Affiliations

Anti-SARS-Cov2 vaccination at the time of the COVID-19 pandemic: suspected adverse events reporting is the milestone of post-marketing surveillance

Alice Mariottini et al. Neurol Sci. 2022 Jul.
No abstract available

PubMed Disclaimer

Conflict of interest statement

The authors declare no competing interests.

Figures

Fig. 1
Fig. 1
Brain and spinal cord MRI undertaken in June 2021. a Sagittal T2-weighted cervical-thoracic spinal cord MRI. Hyperintense T2 lesions in the spinal cord at C3 level (arrow), and T4 level (arrowhead). b Sagittal T1-weighted cervical spinal cord MRI following gadolinium administration, showing contrast enhancement of the demyelinating lesion at C3 level. c Axial T2-weighted cervical spinal cord MRI showing involvement of the posterior columns at the C3 level. d Axial FLAIR brain MRI showing a hyperintense T2 lesion in the right pons
See this image and copyright information in PMC

References

    1. Agency EM (2021) Vaxzevria (previously COVID-19 vaccine AstraZeneca). Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/vaxzevria-previously-c.... Accessed 30 Sept 2021
    1. Voysey M, Clemens SAC, Madhi SA, et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet. 2021;397(10269):99–111. doi: 10.1016/S0140-6736(20)32661-1[publishedOnlineFirst:2020/12/12]. - DOI - PMC - PubMed
    1. Havla J, Schultz Y, Zimmermann H, et al. First manifestation of multiple sclerosis after immunization with the Pfizer-BioNTech COVID-19 vaccine. J Neurol. 2022;269(1):55–58. doi: 10.1007/s00415-021-10648-w. - DOI - PMC - PubMed
    1. Nistri R, Barbuti E, Rinaldi V, et al. Case report: multiple sclerosis relapses after vaccination against SARS-CoV2: a series of clinical cases. Front Neurol. 2021;12:765954. doi: 10.3389/fneur.2021.765954. - DOI - PMC - PubMed
    1. Khayat-Khoei M, Bhattacharyya S, Katz J et al (2021) COVID-19 mRNA vaccination leading to CNS inflammation: a case series. J Neurol:1–14. 10.1007/s00415-021-10780-7 - PMC - PubMed

MeSH terms